Market News

Zydus Lifesciences arm gets FDA priority review for liver disease drug application

The proposed indication is for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have shown an inadequate response to UDCA, or as monotherapy in patients who are unable to tolerate UDCA. Shares of Zydus Lifesciences Ltd ended at ₹1,085.95, up by ₹7, or 0.65%, on the BSE today, May 27.

Zydus Lifesciences buyback alert! Last date to buy shares to participate in Rs 1,100 crore buyback at 7% premium

Investors must purchase Zydus Lifesciences shares by Wednesday, May 27, to be eligible for the Rs 1,100 crore buyback, as the record date is May 29. The company approved buying back up to 95.65 lakh shares at Rs 1,150 each, a 7% premium. This follows strong Q4 results and a dividend recommendation.

6 pharma stocks that Bernstein sees up to 40% upside potential. Do you own any?

​Bernstein initiated coverage on six pharma stocks, expressing a positive outlook on the Indian healthcare sector driven by AI, innovation in niche areas, and a strengthening ecosystem. The brokerage highlighted attractive valuations and easing policy uncertainties, naming Zydus Lifesciences as its top pick with a significant upside potential.

Sakar Healthcare partners with Zydus Lifesciences for GCC Markets

Sakar Healthcare has partnered with Zydus Lifesciences to supply oncology products in GCC countries and other emerging markets. This marks the company's 40th global agreement in the anti-cancer segment. Sakar Healthcare is expanding its international oncology business and strengthening its presence in emerging markets. The company is also progressing with regulatory filings and approvals in highly regulated markets.

Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sector

Bernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future growth for the Indian healthcare sector. Key drivers include AI-led innovation, incremental advancements in niche areas, and improved quality culture. Attractive valuations also support this positive outlook for the industry.

Zydus Lifesciences,3 stocks hit 52-week highs, rally up to 25% in a month

Zydus Lifesciences concludes its investment in Torrent Urja 25

Pursuant to the same, the transaction of subscription of shares of Torrent Urja 25 is consummated on 19 May 2026.

Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?

Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the January-March quarter. A Rs 1,100 crore share buyback was announced. Analysts from Nomura, Nuvama, Motilal Oswal, and JM Financial shared their views on the company's performance and future prospects.

Zydus Lifesciences shares gain nearly 7% on strong US growth outlook; Check price targets

Zydus' specialty pipeline remains the key focus with Desidustat in China, Saroglitazar and Nufymco launches in the US. The management said the specialty business is expected to see a meaningful ramp-up from FY28 onwards.

Zydus Lifesciences Shares Rally After Q4 Result, Share Buyback Announcement

The sharp rally comes on the back of Zydus Life's Q4FY26 earnings, where the company reported a consolidated net profit of Rs 1,272.5 crore for the March quarter, up 8.7% year-on-year.

Zydus Lifesciences shares gain 7%, hit 52-week high on healthy Q4 show

In the March quarter (Q4FY26), Zydus Lifesciences reported a net profit of ₹1,272.5 crore, as compared to ₹1,170.9 crore a year ago, up 8.7 per cent

Zydus Lifesciences share price jumps over 6% after Q4 results. Should you buy or sell?

Zydus Lifesciences shares rose over 6% after strong Q4FY26 earnings, reporting a 14.6% increase in net profit to ₹1,592.9 crore. Revenue grew to ₹7,587 crore, driven by the consumer wellness segment. The board approved a ₹1,100 crore share buyback and a Re 1 dividend.